Background: Targeting radiosensitizer-incorporated nanoparticles to a tumor could allow for less normal tissue toxicity with more efficient drug release, thus improving the efficacy and safety of radiation treatment. The aim of this study was to improve tumor-specific delivery and bioavailability of a nanoparticle-mediated radiosensitizer in mouse brain tumor models. Methods: A pH-sensitive nanoparticle, chitoPEGAcHIS, was conjugated to recombinant peptide HVGGSSV that could bind to tax-interaction protein 1 (TIP-1) as a radiation-inducible receptor. Then the c-Jun N-terminal kinase (JNK) inhibitor, SP600125 was incorporated into this copolymer to fabricate a HVGGSSV-chitoPEGAcHIS-SP600125 (HVSP-NP) nanoradiosensitizer. In vitro and in vivo radiation treatment were performed using a Gamma Knife unit. The tumor targetability of HVSP-NP was estimated by optical bioluminescence. Synergistic therapeutic effects of radiation treatment and HVSP-NP were investigated in Lewis lung carcinoma (LLC) cell-bearing mouse brain tumor models. Results: The SP600125 JNK inhibitor effectively reduced DNA damage repair to irradiated LLC cells. A pH sensitivity assay indicated that HVSP-NP swelled at acidic pH and increased in diameter, and its release rate gradually increased. Optical bioluminescence assay showed that radiation induced TIP-1 expression in mouse brain tumor and that the nanoradiosensitizer selectively targeted irradiated tumors. Radiation treatment with HVSP-NP induced greater apoptosis and significantly inhibited tumor growth compared to radiation alone. Conclusion: As a novel nanoradiosensitizer, HVSP-NP was found to be able to selectively target irradiated tumors and significantly increase tumor growth delay in LLC-bearing mouse brain tumor models. This research shows that delivering a pH-sensitive nanoradiosensitizer to a brain tumor in which TIP-1 is induced by radiation can result in improved radiosensitizer-release in an acidic microenvironment of tumor tissue and in created synergistic effects in radiation treatment.
Introduction
Metastatic brain tumor is the most common intracranial tumor in adults. Its incidence is 10-times more frequent than primary brain tumor. 1 As the survival rate of cancer patients has increased and medical diagnostic imaging has improved, patients with metastatic brain tumor have continued to increase. The most common treatment options for metastatic brain tumors include surgery, chemotherapy, radiotherapy, and their combination. Radiosurgery, such as Gamma Knife radiosurgery (GKR), has become a reasonable alternative to conventional open surgery or traditional radiotherapy. It is an important option in the management of brain metastases. Although radiotherapy is regarded as one of the promising treatment options for cancers, various side-effects have been reported. [2] [3] [4] [5] If the tumor is large, located in the brainstem, or adjacent to critical structures, a satisfactory therapeutic effect cannot be obtained due to insufficient treatment dose. To solve these problems, radiosensitizers have been used to improve the sensitivity of radiation in the tumor. 6, 7 Enhancing the radiosensitivity of the tumor could enable fewer or more effective doses, improving the therapeutic outcome of radiotherapy. It has been reported that c-Jun N-terminal kinase (JNK) activity inhibition can enhance radiosensitivity and apoptosis of tumor cells. 8 JNK belongs to an evolutionarily conserved family of mitogen-activated protein kinases (MAPK). It can be activated by treating cells with cytokines (such as TNF and IL-1) and exposing cells to a variety of environmental stresses. 9 JNK participates in all types of cellular responses including cell death. It is also involved in phosphorylation of H2AX in irradiated cell. [10] [11] [12] JNK-specific inhibitor has been investigated as a radiosensitizer. It has synergistic effects in combination with radiotherapy or chemotherapy. [13] [14] [15] [16] In a recent study, we have demonstrated that by blocking JNK signaling using SP600125, γH2AX expression is decreased and apoptosis is increased in irradiated lung and breast cancer cells. 17 SP600125 can be utilized as a radiosensitizer. Small molecule inhibitors such as SP600125 have no specificity against cancer cells and can spread out in the whole body. This is a significant constraint in applying those drugs to intracranial tumors due to their adverse effects on normal cells and tissues. Nano-medicine technology using nanoparticles, polymeric micelles, and polymer conjugates may overcome such limitation. Nanoparticle-mediated drug formulations can decrease drug related toxicity, provide tumor microenvironment-responsive drug release behavior, and enable improved anticancer activity for tumor tissues. 18, 19 Furthermore, polymeric nanoparticles allow efficient drug transfer to tumor cells over blood-brain barrier (BBB, which inhibits penetration of bioactive molecules including anticancer agents and radiosensitizers), thereby enhancing drug sensitivity in the tumor. [20] [21] [22] [23] Radiation can induce site-specific expression of receptors within the tumor. These radiation-inducible receptors might be targeted by peptides selected by phage display. [24] [25] [26] Irradiation of tumors is known to increase expression levels of TIP-1 receptor before the onset of apoptosis or cell death. 27 In the present study, we used Lewis lung carcinoma (LLC) cell-bearing mouse brain tumor model to investigate nanoparticulate radiosensitizer (nanoradiosensitizer) as a scaffold for establishing a radiation-guided drug delivery system. To increase radiation-specific delivery and improve tumor bioavailability, the nanoradiosensitizer was functionalized with HVGGSSV peptide that could specifically target TIP-1 receptor within irradiated tumors. HVGGSSV peptide-decorated nanoparticle was fabricated. HVGGSSV peptide was conjugated to the end of poly(ethylene glycol) (PEG) to synthesize HVGGSSV-PEG. HVGGSSV-PEG was then conjugated with chitosan to synthesize HVGGSSV-chitoPEG. Drug release from a nanoparticle can be accomplished by using bonds that are sensitive to hydrolytic degradation or pH. 30, 31 To endow pH-sensitivity against nanoparticles, acetyl-histidine (AcHIS) was conjugated to the backbone of chitosan chain to synthesize HVGGSSV-chitoPEGAcHIS. Therefore, HVGGSSVchitoPEGAcHIS copolymer has TIP-1 specific and pH-sensitive properties as a drug deliver carrier. Radiosensitizers including SP600125 can be incorporated into this copolymer, resulting in HVGGSSV-chitoPEGAcHIS-SP600125 (HVSP-NP). We assessed contribution of concomitant HVSP-NP administration in radiation treatment against mouse brain tumors. This approach was able to improve tumor-specific delivery and bioavailability of a radiosensitizer, delay tumor growth, and prolong mouse survival in radiated mouse brain tumor models.
Materials And Methods

Cell Culture And Treatment Protocol
A murine Lewis lung cancer (LLC) cell line was obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (both from Gibco-BLR, Gaithersburg, MD, USA) at 37°C in a 5% CO 2 /95% air incubator. The LLCFluc cell line was transfected with a Lentiviral vector containing firefly luciferase gene. SP600125, a JNK inhibitor, was supplied by Sigma (St. Louis, MO, USA), constituted in dimethyl sulfoxide (DMSO, 10 mM), and stored at −80°C. Cells were irradiated using a Gamma Knife system. 32 After the copolymer capable of acting as a drug deliver carrier was prepared, Ce6 dye was conjugated or SP600125 was incorporated, resulting in functionalized nanoparticles. First, HVGGSSV-PEG conjugates were produced. Briefly, 0.1 mM of PEG-succinimidyl glutarate was dissolved in 5 mL DMSO. Then 1.2 equivalents of HVGGSSV in 5 mL of H 2 O/DMSO mixtures (1/4, v/v) were added. This reaction was magnetically stirred for 24 hours. Reactants were then introduced into a dialysis tube (MWCO: 2,000 g/mol) and dialyzed against deionized water for 1 day with exchanges of water at 2 hour intervals to remove organic solvent and unreacted peptide. Following this, dialyzed solution was lyophilized for 2 days. The yield of product was about 96.9%. Yield=[Weight of product/(feeding weight of PEG +feeding weight of HVGGSSV)]×100. Thereafter, HVGGSSV-chitoPEG copolymer was produced. Briefly, 0.1 mM HVGGSSV-PEG conjugates dissolved in 5 mL DMSO was mixed with 180 mg of WSC in 10 mL H 2 O/ DMSO mixtures (1/4, v/v). This was magnetically stirred for 24 hours. After that, the mixture was introduced into a dialysis tube (MWCO: 8,000 g/mol). Dialysis was continued for 2 days with exchanges of water at 2-3 hours intervals to remove organic solvent and unreacted products. Following this, dialyzed solution was lyophilized for 3 days. The yield of product was higher than 98%. Yield= [Weight of product/(feeding weight of HVGGSSV-PEG conjugates+feeding weight of WSC)]×100. Finally, HVGGSSV-chitoPEGAcHIS copolymer was produced as a drug deliver carrier. Briefly, 78.8 mg AcHIS dissolved in 5 mL DMSO was mixed with equivalent amounts of EDAC and NHS to activate carboxylic acid of AcHIS. This was reacted for 24 hours by magnetic stirring. It was then mixed with 295 mg HVGGSSV-chitoPEG copolymer dissolved in 10 mL H 2 O/DMSO mixtures (1/4, v/v). This reaction was further stirred for 24 hours. After that, the reactant was introduced into the dialysis tube (MWCO: 12,000 g/mol). Dialysis was continued for 2 days with exchanges of water at 2-3 hour intervals to remove organic solvent and unreacted products. Following this, dialyzed solution was lyophilized for 3 days. The yield of product was about 97.3%. Yield [Weight of product/(feeding weight of HVGGSSV-chitoPEG conjugates+feeding weight of AcHIS)]×100. The content of Ac HIS in the final product (HVGGSSV-chitoPEGAcHIS copolymer) was estimated to be 18.9% (w/w) using the following formula: Content of Ac HIS=[(Weight of final product-feeding weight of HVGGSSV-chitoPEG copolymer)/Weight of final product]×100. Ce6-conjugated HVGGSSV-chitoPEGAcHIS copolymer was produced for confirming drug delivery. First, 3 mg Ce6 was activated with an equivalent amount of EDAC/NHS system in 2 mL DMSO. This was added to 27 mg HVGGSSV-chitoPEGAcHIS copolymer in 5 mL H 2 O/DMSO mixtures (1/4, v/v). This reaction was further stirred for 24 hours. After that, the reactant was introduced into the dialysis tube (MWCO: 12,000 g/mol). Dialysis was continued for 1 day with exchanges of water at 2-3 hour intervals to remove organic solvent and unreacted products, resulting in nanoparticles. Following this, dialyzed solution was lyophilized for 3 days. The content of Ce6 was calculated to be about 8.7% (w/w) based on measurement at 664 nm with a UV spectrophotometer (UV-1601, Shimadzu Co. Ltd. Osaka, Japan) using the following formula: Content of Ce6=[(Weight of final product-feeding weight of HVGGSSV-chitoPEGAcHIS copolymer)/Weight of final product]×100.
Fabrication Of SP600125 Incorporated pH-Sensitive Nanoradiosensitizer HVGGSSV-chitoPEGAcHIS copolymers (45 mg) were distributed in 3 mL water with 20-second sonication (1s×20) using an ultra-sonicator (Sonics, VCX-750, Sonics & Materials Inc., CT, USA) and 4 mL of DMSO was added. SP600125 (5 mg) dissolved in 3 mL DMSO was then added and stirred for 20 minutes. The mixture was then introduced into a dialysis tube (MWCO=8,000 g/mol) and dialyzed against water for 1 day with exchange of distilled water at 3 hour intervals, resulting in HVGGSSV-chitoPEGAcHIS-SP600125 nanoparticle (HVSP-NP). Dialyzed solution was used for analysis or lyophilized for 3 days. Empty nanoparticles (E-NP) were fabricated in a manner similar to that described above, but without drug. To measure drug contents, 5 mg lyophilized solid was dissolved in DMSO and then stirred for 3 hours. PL contents were measured using a UV-spectrophotometer (UV-1601, Shimadzu Co. Ltd. Osaka, Japan) at 320 nm. Drug contents were calculated as follows: drug content (%, w/w)=(SP600125 weight/total weight of nanoparticle)×100. E-NP was used for blank test. 
Analysis Using 1 H Nuclear Magnetic Resonance (NMR) Spectroscopy
Characterization Of HVSP-NP Nanoradiosensitizer
HVSP-NP is a functional nanoparticulate radiosensitizer. Morphologies of nanomaterials were observed using a fieldemission scanning electron microscope (S-4800; Hitachi, Tokyo, Japan) at 10 kV or 15 kV. Nanoparticle solution prepared as described above was dropped onto a cover slide and dried at room temperature for 6 hours. Particle size and zeta potential were measured using a Zetasizer Nano-ZS (Malvern, Worcestershire, UK). The concentration of nanoparticles was adjusted to be 0.1% (w/w).
A drug release test of HVSP-NP was performed. The dialyzed solution as described above was adjusted to 30 mL. Then 7 mL of this solution was placed into a dialysis membrane (MWCO: 12,000 g/mol). The dialysis membrane was then introduced into a 50 mL Falcon tube containing 43 mL phosphate-buffered saline (PBS, 0.01M, pH 7.4) and then agitated at 100 rpm (37°C). Whole media were taken to measure the released amount of SP600125 from nanoparticle (HVSP-NP) and then replaced with fresh media. The concentration of SP600125 was measured with a UV-spectrophotometer (UV-1601, Shimadzu Co. Ltd. Osaka, Japan) at 320 nm. E-NP was used for blank test. pH of media was adjusted to be 5~7.4 to investigate the effect of pH on drug release behavior.
MTT Assay
To assess the toxicity of HVSP-NP, cell metabolic activity was estimated using 3-(4,5-dimethylthiazol-2-yl) - ) were diluted in 3 µL PBS and stereotactically inoculated (1 µL/min) into mouse brain. Cell line infusion site was located by identifying the intersection of sagittal and coronal sutures to define bregma and then measuring 2 mm right lateral and 1 mm posterior of the bregma. Injection depth was adjusted to 3 mm. Nanoparticles were given by tail vein injection without premedication.
Western Blotting And Immunohistochemistry (IHC)
Western blotting was conducted according to the protocol established in previous studies. 17, 34, 35 Briefly, harvested cells were lysed with RIPA buffer containing Tris-HCl (pH 7.5), 1% Triton X-100, 0.15 M NaCl, 0.5% sodium deoxycholate, and 2 mM EDTA (Bio-solution). Proteins extracted from whole cell lysates (30 μg) were subjected to electrophoresis using 10% SDS-polyacrylamide gel at 100 V for 2 hours and then transferred to PVDF membranes at 100 V for 1 hour on ice. Membranes were blocked with 5% non-fat dry milk for 1 hour at room temperature, incubated with following primary antibodies at 4°C overnight: GAPDH (1:2,000, CST), anti-TIP-1 (1:5,000; Abcam), p-JNK (1:200; Santa Cruz Biotechnology), and phospho-histone H2AX (Ser139) rabbit monoclonal antibodies (1:1,000, CST). A horseradish peroxidase-conjugated goat anti-rabbit IgG (1:3,000; CST) was used as a secondary antibody. Protein detection and levels were determined using Amersham imager 600 (Amersham Biosciences). IHC was carried out as previously described. 36, 37 Briefly, brains were removed from sacrificed mice, fixed with 10% formaldehyde solution, and then used to prepare paraffinembedded block. Consecutive 3 μm-thick tissue sections from blocks were then transferred to poly-L-lysine-coated slides for IHC analysis. Slides were dewaxed in xylene for 15 minutes, hydrated with ethanol solution series of low concentration (60%, 80%, 100%) for 10 minutes, and then washed with distilled water for 10 minutes. For IHC staining with γ-H2AX and TIP-1, slides were subjected to heat-induced epitope retrieval that involved pre-heating using high pressure and EnVision FLEX Target Retrieval low pH solution (Dako). Endogenous peroxidase activity was quenched by peroxidaseblocking solution (Dako) for 30 minutes. Non-specific protein binding was blocked with antibody diluent solution (Dako) for 30 minutes. Primary antibodies used for staining were as follows: rabbit Anti-TIP-1 antibody (1:100; Abcam) and rabbit phospho-histone H2AX (Ser139) antibody (1:500; Cell Signaling). Primary antibody was added and incubated at 4°C overnight. After washing with PBST, ImmPRESS universal reagent anti-mouse/rabbit Ig (Vector laboratories, Inc.) was used as a secondary antibody and incubated with samples at room temperature for 1 hour. After washing with PBST, DAB (Vector laboratories, Inc.) was added and the reaction was stopped by washing as soon as the color changed to brown. Harris hematoxylin was used for counterstaining.
Bioluminescence Imaging
Bioluminescence images (BLI) of the mouse brain tumor were acquired with a Night Owl In Vivo Imaging System (Berthold technologies, Bad Wildbad, Germany). Anesthetized mice with isoflurane (2.5% in air) were placed in the system. Then 3 mg D-luciferin (PerkinElmer) was intraperitoneally injected into each mouse. Photons emitted from the tumor expressing luciferase were collected for 2 minutes. Pseudo-color images indicating photon counts were analyzed using IndiGo software (Berthold technologies).
Statistical Analyses
Descriptive statistics are presented as mean±standard deviation (SD) or range. Independent-samples t-test was used for between-group comparisons. All statistical analyses were performed using SPSS version 19.0 (SPSS Inc., Chicago, IL, USA), with significance level set at P<0.05.
In Vitro And In Vivo Irradiation Conditions
LLC cultures were irradiated using dedicated in vitro apparatus for Leksell Gamma Knife (LGK). Cultured cells were placed at 6*10 6 cells/tube in conical culture tubes and then centrifuged. They were collected at the bottom of the tube to form a constant target volume. Radiation dose was adjusted using Leksell GammaPlan (LGP). Mouse brain tumor was also irradiated with LGK. The mouse was positioned on a dedicated adaptor for small animal and its head midline was aligned to the center axis of the adaptor. Fractionated radiation was exposed to mouse brain. Radiation dose applied to the mouse was computed on the basis of a linear quadratic model. Biologically effective dose (BED) was calculated with the following equation:
Where n was the number of fractions and d was the dose/fraction. α/β ratio was assumed to be 3 Gy for lateresponding tissues such as brain and 10 Gy for earlyresponding tissues such as tumors. 38 
Results
Synthesis And Characterization Of HVSP-NP
To synthesize HVGGSSV-chitoPEGAcHIS copolymer, amine end group of HVGGSSV hexapeptide was conjugated with PEG-succinimidyl glutarate as shown in Figure 1A . Specific peaks of peptide were confirmed at 2.6-3.0 ppm, 6.8 ppm, and 7.5 ppm, while ethylene protons of PEG were confirmed at 3.4 ppm. Basically, HVGGSSV-PEG-g-chitosan copolymer was designed to become 10 molecules of HVGGSSV-PEG against 100 glucosamine. At 1 H NMR results, (1H, 4) proton of glucosamine and ethylene proton of PEG appeared at 4.2~4.4 ppm and 3.4~3.5 ppm, respectively. From these results, proton of 1H and ethylene proton was compared to estimate substitution degree (DS) of HVGGSSV-PEG in HVGGSSV-chitoPEG copolymer. The number of DS of PEG versus 100 glucosamine was about 9.2. HVGGSSV-PEG conjugates were further conjugated with WSC and then AcHIS was attached to the backbone of chitosan to endow pH-sensitivity. 1 H NMR spectra of HVGGSSVchitoPEGAcHIS copolymer are shown in Figure 1B . Specific peaks were confirmed at 1.6~2.6 ppm for acetyl histidine and at 3.2~4.2 ppm for chitosan. These results indicated that HVGGSSV-chitoPEGAcHIS copolymer was successfully synthesized.
As a pH-sensitive nanoradiosensitizer, HVSP-NP was prepared with sonication and dialysis procedure as described above. E-NP was prepared similarly in the absence of SP600125. As shown in Figure 2A , SEM photos indicated that E-NP and HVSP-NP had spherelike shape and small particle sizes of less than 100 nm and 200 nm, respectively. Properties of particles were measured. Results are shown in Table 1 .
Since HVSP-NP has pH-sensitivity, particle size changes were measured by pH variation, as shown in Figure 2B . Particle sizes of both E-NP and HVSP-NP were gradually increased at acidic pH. Their average sizes at pH 5 were at least 3-times larger than those at pH 7.4. These results indicated that HVSP-NP was swelled at acidic pH and its diameter was increased. HIS group of chitosan backbone was composed of hydrophobic core of nanoparticles due to hydrophobicity of HIS moiety. However, hydrophobic properties of HIS were relatively hydrophilic in acidic media and then nanoparticles were swelled in the acidic environment. Figure 2C shows drug release behavior from HVSP-NP. As shown in Figure 2C top, higher drug contents in nanoparticles resulted in slower release from nanoparticles. These results might be due to the fact that hydrophobic drug is easily aggregated in the core of nanoparticles with high drug contents, causing the drug to be dissolved slowly compared to nanoparticles with lower drug contents. The effect of pH on drug release rate from nanoparticles was also assessed by changes of media pH as shown in Figure 2C -bottom.
Drug release rate from nanoparticles was gradually increased at acidic pH. These results were due to the fact that nanoparticles were swelled in acidic solution with increased diameters of nanoparticles, resulting in increased drug release.
Responses Of LLC Cell Line To Irradiation And HVSP-NP
To verify cellular radiation response of LLC cell lines to focused gamma beam of LGK driven-in vitro apparatus, cell survival curve was plotted on a log-linear scale with dose on the linear x-axis using clonogenic assay ( Figure 2D -left). Survival curves for mammalian cells are usually presented in the form shown in this plot. The survival curve on the log-linear plot starts out straight with a finite initial slope at low doses, bends at higher doses, and tends to straighten again at very higher doses. 39 This in vitro apparatus showed good performance in verifying radiation response of cell line to gamma ray exposure. MTT assay results showed that the optical density of LLC cells was dose-dependently decreased after treatment with HVSP-NP ( Figure 2D right). The IC 50 value of this radiosensitizer was calculated to be 19.26 μM (R 2 =0.96).
Targeting The Nanoradiosensitizer To Radiation-Inducible Receptors Improved Tumor-Specific Drug Delivery TIP-1 is a radiation-inducible antigen on the surface of tumor cells that can bind peptide ligand HVGGSSV. Western blotting was carried out to determine TIP-1 expression in irradiated LLC ( Figure 3A ). In the samples irradiated with 8 Gy, the highest induction of TIP-1 was observed at 16 hours after irradiation, while it was mildly reduced at 24 hours post-irradiation ( Figure 3A -upper left). After 16 hours of irradiation, the degree of TIP-1 expression was assessed according to irradiation doses. Results showed that the amount of TIP-1 expression was increased as radiation dose increased ( Figure 3A -upper right). Relative band quantification was determined by ImageJ, by normalizing to loading control, GAPDH. Histograms (below Western blot) reveal TIP-1 expression levels (abbreviations: n.s., not significant by Log rank test; *P<0.05). Error bars represent mean±standard deviation (SD). IHC staining also revealed higher levels of TIP-1 protein in irradiated tumors than those in untreated controls ( Figure 3B ). Each immunoreactivity pattern was evaluated by quadruplicate specimens from the same mouse. Scale bar, 10 μm. An IVIS optical imaging study was conducted to determine whether targeting the nanoradiosensitizer to radiation-inducible receptors could improve tumor-specific drug delivery. We synthesized HVGGSSVchitoPEGAcHIS copolymer by conjugating HVGGSSV peptide to pH-sensitive nanoparticles. This copolymer was then labeled with a fluorescent probe (Ce6) for in vivo fluorescence imaging studies. Figure 3C shows the IVIS study timeline to identify tumor targetability of HVSP-NP. Mice were classified into four categories of control, untreated (0 Gy), single fraction (2 Gy), and multi fraction (10 Gy=6.2 Gy*2). Bioluminescence images of mice were acquired at 10 days post-LLC cell injection. Mice bearing LLC brain tumors were treated with 0 Gy, 2 Gy, or fractionated 10 Gy (6.2 Gy×2) and administered HVGGSSVchitoPEGAcHIS labeled with Ce6 (0.2 mg). As shown in Figure 3D , the bioluminescence images were reacquired at 7 days post-treatment. Tumor growth of radio-treated mice (2 Gy or f.10 Gy) was delayed compared to that of untreated (0 Gy) control mice. Fluorescence images were acquired and Ce6 dye signals were measured to verify drug delivery to the tumor. Irradiated tumor models showed greater radiance compared to untreated (0 Gy) control. Radiance increased as radiation dose increased (2 Gy and f.10 Gy). Histograms show the intensity of dye fluorescence (abbreviations: n.s., not significant by Log rank test; *P<0.05). Error bars indicate ±SD; columns, mean. In addition, the tumor within brain section was verified by H&E staining. It was then immunostained with TIP-1 antibody. Minimal staining of normal tissue and substantially increased staining of tumor cells were observed ( Figure 3E ). The level of TIP-1 increased more in tumor than in normal tissues, and non-specific stain was observed in the brain cortex. These results revealed that targeting HVGGSSV-conjugated nanoradiosensitizer to radiation-inducible receptor (TIP-1) could improve tumorspecific drug delivery.
Targeted Nanoradiosensitizer Enhances Therapeutic Efficacy In Mouse Brain Tumor Model
The synergy effect of HVSP-NP with radiation treatment was investigated by survival assay, in which LLC cellbearing mouse brain tumor models were grouped (n=8) as control, HVSP-NP alone, RT alone, and RT with HVSP-NP. Figure 4A shows representative mouse brain MRI (T1 enhanced) in control, RT alone, and RT with HVSP-NP groups. MRI was scanned at 7 days after cell injection and 12 days after treatment. Tumor growth rate was measured to be 7.57 for control, 4.85 for RT alone, and 2.55 for RT with HVSP-NP. Tumor volume was measured using Leksell GammaPlan ® (LGP, Dedicated treatment planning tool specifically designed for stereotactic radiosurgery). This result revealed that HVSP-NP delayed tumor growth in radiation treatment of mouse brain model. As shown in Figure 4B , survival assay was performed with KaplanMeier curve (abbreviations: n.s., not significant by Log rank test; *P<0.05; ***P<0.0001). The group treated with only HVSP-NP did not noticeably affect the survival of mice, whereas the radiation treatment group significantly prolonged the survival compared to other groups. Especially, combination of radiation and HVSP-NP significantly (P=0.03) prolonged the survival compared to RT alone. To verify the effect of HVSP-NP on irradiated mouse brain tumor, tumor sections were immunostained for p-JNK, γH2AX, and Cleaved Caspase 3 ( Figure 4C ). Each immunoreactivity pattern was confirmed by quadruplicate specimens from the same mouse. Scale bar, 10 μm. In radiation-induced cells, JNK signalings are known to mediate the phosphorylation of H2AX. RT with HVSP-NP treatment induced a decrease in p-JNK and γH2AX expression compared to RT alone. To evaluate the mechanism of cell death, tumor sections were also immunostained for cleaved caspase-3 expression as an apoptosis marker. RT with HVSP-NP treatment produced greater apoptosis compared to RT alone. The histograms show the quantitative analysis of p-JNK, γH2AX, and cleaved Caspase3 expression levels for RT alone and RT with HVSP-NP (abbreviations: n.s., not significant by Log rank test; *P<0.05). Error bars indicate ±SD; columns, mean. These results suggest that HVSP-NP can suppress repair of cell damage by inhibiting p-JNK, eventually inducing more apoptosis.
Discussion
The prescription dose of radiation surgery is limited by the location or size of the tumor. Even if the tumor is under the critical boundary condition, an improved therapeutic effect can be expected while minimizing side-effects with relatively small doses by modulating radiation sensitivity of the tumor. However, most radiosensitizers have no targetability against cancer cells. They spread throughout the whole body. That is, a radiosensitizer-drug without sufficient tumor selectivity can compromise drug efficacy and induce undesired side-effects. Tumor-specific drug delivery systems have been investigated using various targeting mechanisms, in which peptides, aptamers, antibodies, antigens, and so on are subjects of studies. 40, 41 Particularly, since peptide has various characteristics including high affinity, lower molecular weight, lack of immunogenicity, and absorption by tumor cells, it has been extensively studied as a targeted drug carrier. 42, 43 HVGGSSV peptide can distinguish irradiated tumors from untreated tumors and normal tissues, suggesting that this peptide has high potential in radiation-guided drug delivery to the tumor. 44, 45 HVGGSSV has been actively studied as a tumor-targeting peptide that is capable of binding to radiation-induced receptors. HVGGSSV peptide can bind to TIP-1 receptors within a tumor and irradiation can be used to induce site-specific of these receptors. 25 These peptides can then be modified with cytotoxic drug-incorporated nanoparticles to establish radiation-guided drug delivery systems. 24 The nanomedicine delivery system based on receptor expression and stimuli in tumor cells has been extensively studied due to its superiorities in targeting specific tissues with minimized normal tissue toxicity. [46] [47] [48] [49] [50] Since tumor microenvironment causes various abnormal changes unlike normal tissues, these mechanisms can be investigated and applied to a nanomedicine drug delivery system. 51 61 reported that Ac-His-conjugated chitosan nanoparticles showed the acidic pH-triggered aggregation and disassembling properties. They also argued that drug release rate was accelerated in the acidic pH due to the pH-sensitivity of Ac-His and then efficiently suppressed breast tumor cells in vitro. We also observed that the diameter of nanoparticles was increased and then the drug release rate was also increased at acidic pH, ie, increase of nanoparticle surface at acidic pH may induce the opportunity of drug liberation from nanoparticles. Thie behavior of AcHIS-conjugated nanoparticles induced faster drug release in the acidic pH environment of the tumor. In this research, we tried to establish an intelligent radiosensitizer (HVSP-NP) delivery system based on radiationguided peptide HVGGSSV and chitoPEGAcHIS nanoparticle sensitive to acidity (pH). We also assessed its synergy effect with radiotreatment. This approach can provide a means to target radiosensitizer specifically to irradiated brain tumor and to release this drug continuously in peritumoral environment. We have already revealed that SP600125 can increase the radiosensitivity in an irradiated subcutaneous tumor model. 17 The current study was intended for a LLC-cell bearing mouse brain tumor model, focusing on tumor specific delivery of HVSP-NP as a radiosensitizer. In these brain models, even though nanoparticles can be given by tail vein injection, this condition alone remains difficult for nanoparticles to be delivered into the brain because of the BBB. Although the integrity of BBB establishes a stable internal environment of the brain, BBB can be disrupted by osmotic disruption, bradykinin, or irradiation. 62 Therefore, focused gamma ray irradiation will cause tumor cell kill and may improve BBB penetration of HVSP-NP. NMR spectroscopy revealed that drug deliver carrier HVGGSSVchitoPEGAcHIS was successfully synthesized. SP600125 was incorporated to this carrier and its characteristics were evaluated. Two forms of HVSP-NP with different particle sizes and drug contents were obtained: (1) HVSP-NP I with a size of 80.3±4.1 nm and a drug content of 7.3%; and (2) HVSP-NP II with a size of 118.4±20.8 nm and a drug content of 11.2%. Particle sizes of HVSP-NP I and II showed a monomodal distribution pattern. Experimental drug loading was lower than the theoretical one because SP600125 was liberated during the dialysis procedure. As a result of drug release test and particle swelling evaluation, drug release rate from nanoparticles was gradually increased at acidic pH, presumably because nanoparticles were swelled in the acidic solution and then increased diameters of nanoparticles which resulted in increased drug release. This finding suggests that in a peritumoral microenvironment where acidity is increased, drug can be effectively released from the nanoparticle. We found that nanoradiosensitizer HVSP-NP could specifically target irradiated mouse brain tumors in our in vivo evaluation. This result shows that radiation can be utilized to induce the expression of TIP-1 within tumor microvasculature and significantly enhance the delivery of nanoparticles to the tumor site. Thus, conjugation with HVGGSSV can advance intratumoral biodistribution of nanoradiosensitizer and enhance tumor bioavailability, resulting in improved brain tumor growth delay. Furthermore, mouse survival assay confirmed that radiation treatment with a nanoradiosensitizer could significantly improve tumor growth delay compared to radiation treatment alone.
Conclusion
Our study shows that intelligent radiosensitizer HVSP-NP has intratumoral TIP-1 specific and pH-sensitive properties as a radiosensitizer deliver carrier and that its synergy with radiation treatment can improve brain tumor growth delay in in vivo assay. Recently, radiosurgery is used as an alternative to conventional craniotomy. Simultaneous treatment with nanoradiosensitizers may be another option to improve efficacy of high energy radiation and enhance cure rates for brain tumors.
